Loading
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
D9319C00001- 1L OC Mono Global RCT is a phase 3 interventional study registered as NCT04884360 by AstraZeneca, with 366 participants enrolled, started 2021-05-31 and due to reach its primary completion in 2026-07-27. Interventions recorded: Olaparib, Matching placebo. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares High-grade serous ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/